Sign up
Log in
Replimune posts IGNYTE trial presentation on RP1-nivolumab in anti-PD-1-failed melanoma
Share
Listen to the news
Replimune posts IGNYTE trial presentation on RP1-nivolumab in anti-PD-1-failed melanoma
  • Replimune published updated IGNYTE trial results for RP1 with nivolumab in anti-PD-1-failed melanoma, reporting 3-year overall survival outcomes.
  • Median overall survival was 32.9 months; 3-year overall survival rate was 47.8%.
  • Objective response rate by RECIST 1.1 was 33.6%, including a 16.4% complete response rate; median duration of response was 24.8 months.
  • Safety profile remained consistent, with no new safety signals; grade 3-4 treatment-related adverse events occurred in 12.8% of patients.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Replimune Group Inc. published the original content used to generate this news brief on May 30, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
Terms of Service·Privacy Policy·Data Disclaimer
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved